ஃபேபியன் டெனன்பாம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Bellerophon Provides Clinical Program Update and Reports First Quarter 2021 Financial Results
WARREN, N.J., May 11, 2021 (GLOBE NEWSWIRE) Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2021.
“Bellerophon remains focused on advancing its INOpulse® inhaled nitric oxide therapy in multiple high-value areas of unmet need as expeditiously as possible,” said Fabian Tenenbaum, Chief Executive Officer of Bellerophon. “Enrollment in our ongoing pivotal Phase 3 REBUILD study for fibrotic interstitial lung disease, or fILD, patients at risk of associated pulmonary hypertension continues to advance. We also anticipate top-line results from our Phase 2 dose escalation study of INOpulse in sarcoidosis, or PH-Sarc, later this y ....

United States , San Diego , Fabian Tenenbaum , Brian Ritchie , Exchange Commission , University Of California , Hc Wainwright Global Life Sciences Conference , Bellerophon Therapeutics Inc , Clinical Program , Bellerophon Therapeutics , Chief Executive Officer , Program Highlights , San Diego Shortness , Breath Questionnaire , Global Life Sciences , Quarter Ended March , Private Securities Litigation Reform Act , Annual Report , Sci Advisors , ஒன்றுபட்டது மாநிலங்களில் , சான் டியாகோ , ஃபேபியன் டெனன்பாம் , பிரையன் ரிச்சி , பரிமாற்றம் தரகு , பல்கலைக்கழகம் ஆஃப் கலிஃபோர்னியா , ஹ்ஸீ வேந்‌ரைட் உலகளாவிய வாழ்க்கை அறிவியல் மாநாடு ,